Accelerating translational research for drug discovery.
The Drug Discovery Hub, launched in June 2024 and based at the London Biofoundry represents a ground-breaking partnership between Imperial College London and the MRC Laboratory of Medical Sciences (LMS). The Hub aims to bridge the gap between basic and translational research by enabling high-throughput screening of different drug modalities on state-of-the-art platforms. With a mission to advance drug discovery and development, the Hub serves as a collaborative, multidisciplinary platform where scientists from academia and industry partners collaborate to accelerate scientific breakthroughs towards impact.
We are committed to fostering innovation through cutting-edge technologies, data-driven approaches, and a focus on translational research. By integrating expertise from pharmacology, synthetic biology, chemistry, and computational sciences, we aim to tackle unmet medical needs and pave the way for new treatments that improve patient outcomes.
What We Do
- Collaborative Research: Bringing together leading scientists from our academic and industrial ecosystems to overcome key challenges in drug development.
- Technology Integration: Utilizing state-of-the-art methodologies, including AI-driven drug design, high-throughput screening and structural biology.
- Training and Development: Equipping the next generation of researchers with cutting-edge skills and insights in drug discovery and translation.
- Global Partnerships: Building alliances with academic institutions, biotech companies, and healthcare organizations to accelerate the journey from bench to bedside.
The Hub also serves as a cutting-edge technology platform to enhance education and the student experience at Imperial College, creating opportunities for interdisciplinary learning and hands-on research in drug discovery.
The Drug Discovery Hub academic strategy project is led by Professor Edward Tate (GSK Chair in Chemical Biology, Department of Chemistry), Dr Marko Storch (Director Biofoundry Operations) and Professor Paul Freemont (Chair in Protein Crystallography, Department of Infectious Disease).
Visit www.drugdiscoveryhub.org to learn more about our work, explore partnership opportunities and join us in advancing global health.